Travere Therapeutics' Asset Writedowns and Impairment fell 17.96% to -$1.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 108.63%. This contributed to the annual value of $2.8 million for FY2024, which is 7.24% down from last year.
As of Q4 2022, Travere Therapeutics' Asset Writedowns and Impairment stood at -$1.0 million, which was down 413.37% from $329,000 recorded in Q3 2022.
Over the past 5 years, Travere Therapeutics' Asset Writedowns and Impairment peaked at $25.5 million during Q1 2019, and registered a low of -$1.0 million during Q4 2022.
In the last 3 years, Travere Therapeutics' Asset Writedowns and Impairment had a median value of $475,000 in 2021 and averaged $418,000.
Per our database at Business Quant, Travere Therapeutics' Asset Writedowns and Impairment plummeted by 139.28% in 2021 and then skyrocketed by 94.87% in 2022.
Over the past 4 years, Travere Therapeutics' Asset Writedowns and Impairment (Quarterly) stood at $25.5 million in 2019, then reached $2.2 million in 2020, then plummeted by 139.28% to -$874,000 in 2021, then fell by 17.96% to -$1.0 million in 2022.
Its last three reported values are -$1.0 million in Q4 2022, $329,000 for Q3 2022, and $792,000 during Q2 2022.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value